BCIQ Profiles

Company Profile Report
0430 Quick Takes
BioCentury & Getty Images


April 30 Quick Takes: Bilenker has $212M to build newco Treeline’s toolbox; plus Farxiga, Opdivo, BioCryst, Leo, Hikma and more  

May 1, 2021 | 1:18 AM GMT

An SEC filing released Friday revealed that Josh Bilenker and Jeffrey Engelman have $212 million to begin building newly launched Treeline Biosciences Inc.’s toolbox for chasing validated but difficult-to-drug cancer targets. The company quietly launched this week via a LinkedIn post by the Loxo Oncology Inc. co-founder and CEO that listed Engelman, the former Novartis Institutes for BioMedical Research global

Read the full 905 word article

How to gain access

Continue reading with a
two-week free trial.